Objective: To investigate the clinical value of active immunotherapy in the treatment of IVF-ET RSA. Methods: We retrospectively analyzed 62 cycles of IVF/ICSI RSA among 42 infertile couples during July 2003 to April 2011.The RSA patients were treated by active immunotherapy combined with tocolysis using HCG or Progesterone after pregnancy. Results: The number of embryo transferred was 116,the average number of embryo transferred was 1.87 ± 0.61,and the endometrial thickness of HCG day was (9.08 ± 2.03) mm. The achievement rate was 64.29%(27/42),the pregnancy achievement rate behind immunotherapy treatment was 96.43%(27/28),the embryo implantation rate was 28.45%(33/116),the biochemical pregnancy rate was 50.00%(31/62),the clinical pregnancy rate was 45.16%(28/62),the miscarriage rate was 3.57%(1/28),the live birth rate was 24.19%(15/62),the cesarean section rate was 93.33%(14/15). Conclusion: In IVF/ICSI RSA,the active immunotherapy can improve the patient immunity reactivity,effectively reduce the miscarriage rate,and improve the successful pregnancy. So it is a safe and simple treatment.